A form of Parkinson's disease caused by mutations in a gene known as PINK1 has long been labeled rare. But our research shows ...

J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc (NASDAQ:AMRX), noting the company’s generics business is increasingly ...

Mitsubishi Tanabe Pharma (MTPC) today announced that the European Medicines Agency (EMA) has accepted for review the ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 February, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company d ...

Based on EMA's guidance, IRLAB can now proceed with preparations for the registration studies of the drug candidate, which has demonstrated efficacy in a phase Ib and in two Phase II studies against ...

Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib 36-month data Study demonstrated favorable safety profile and continued positive trends in assessed clinical outcome measures ...

Learn more about the MSA treatment landscape @ Drugs for Multiple System Atrophy Treatment The drug used to treat Parkinson's ...

In his regular column, Dr James Le Fanu answers your questions. This week, a reader is concerned by a neighbour who is ...

Parkinson's Disease Treatment Market Aging Populations and Advancements in Deep Brain Stimulation, Gene Therapy, and Medications Fuel Marke ...

Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,500 ...

GOTHENBURG, SE / ACCESS Newswire / February 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 12, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company d ...

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults with advanced Parkinson disease.